Inflammatory mechanisms affecting the lipid profile in patients with systemic lupus erythematosus
- PMID: 17659756
Inflammatory mechanisms affecting the lipid profile in patients with systemic lupus erythematosus
Abstract
Objective: Increased low density lipoprotein (LDL) cholesterol and triglycerides, and decreased high density lipoprotein (HDL) cholesterol concentrations are associated with adverse cardiovascular risk in the general population. Patients with systemic lupus erythematosus (SLE) have an altered lipid profile characterized by increased triglycerides and decreased HDL cholesterol concentrations. We examined the relationships between lipid concentrations, cytokines, and inflammatory markers in patients with SLE.
Methods: Fasting lipid concentrations, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were measured in 110 patients with SLE. Disease activity was quantified by the SLE Disease Activity Index (SLEDAI), and disease damage by the Systemic Lupus International Collaborating Clinics (SLICC) score. Concentrations of circulating tumor necrosis factor-alpha (TNF-alpha), interleukin 6 (IL-6), and insulin were measured and insulin sensitivity calculated.
Results: Lower concentrations of HDL cholesterol were independently associated with higher ESR (p < 0.001), IL-6 (p = 0.02), SLEDAI (p = 0.04), and TNF-alpha (p = 0.04) after adjustment for age, sex, race, body mass index, insulin sensitivity, and current use of corticosteroids or hydroxychloroquine. Triglyceride concentrations were associated with higher CRP concentrations (p = 0.02) and SLICC score (p = 0.04).
Conclusion: Deleterious changes in lipid profile are independently associated with higher concentrations of markers and mediators of inflammation and disease activity and damage in patients with SLE.
Similar articles
-
Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors.J Rheumatol. 2006 Mar;33(3):539-45. Epub 2006 Feb 1. J Rheumatol. 2006. PMID: 16463434
-
Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus.Arthritis Rheum. 2003 Sep;48(9):2533-40. doi: 10.1002/art.11264. Arthritis Rheum. 2003. PMID: 13130473
-
Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus?Arthritis Rheum. 2004 Nov;50(11):3610-5. doi: 10.1002/art.20630. Arthritis Rheum. 2004. PMID: 15529371
-
Mechanisms of dyslipoproteinemias in systemic lupus erythematosus.Clin Dev Immunol. 2006 Jun-Dec;13(2-4):203-8. doi: 10.1080/17402520600876945. Clin Dev Immunol. 2006. PMID: 17162363 Free PMC article. Review.
-
CRP and the disposal of dying cells: consequences for systemic lupus erythematosus and rheumatoid arthritis.Autoimmunity. 2007 Jun;40(4):295-8. doi: 10.1080/08916930701358925. Autoimmunity. 2007. PMID: 17516213 Review.
Cited by
-
The influence of inflammation on cardiovascular disease in women.Front Glob Womens Health. 2022 Oct 11;3:979708. doi: 10.3389/fgwh.2022.979708. eCollection 2022. Front Glob Womens Health. 2022. PMID: 36304737 Free PMC article. Review.
-
Development of High Fat Diet-Induced Hyperinsulinemia in Mice Is Enhanced by Co-treatment With a TLR7 Agonist.Front Physiol. 2022 Jul 6;13:930353. doi: 10.3389/fphys.2022.930353. eCollection 2022. Front Physiol. 2022. PMID: 35874527 Free PMC article.
-
Sex Differences in Lipid Metabolism: Implications for Systemic Lupus Erythematosus and Cardiovascular Disease Risk.Front Med (Lausanne). 2022 May 31;9:914016. doi: 10.3389/fmed.2022.914016. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35712086 Free PMC article. Review.
-
Altered Germinal-Center Metabolism in B Cells in Autoimmunity.Metabolites. 2022 Jan 5;12(1):40. doi: 10.3390/metabo12010040. Metabolites. 2022. PMID: 35050162 Free PMC article. Review.
-
Cardiovascular risk in patients with spondyloarthritis and association with anti-TNF drugs.Ther Adv Musculoskelet Dis. 2021 Jul 27;13:1759720X211032444. doi: 10.1177/1759720X211032444. eCollection 2021. Ther Adv Musculoskelet Dis. 2021. PMID: 34377159 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous